📇 Rhumatologue ·

M VAN HUAN JOSEPH TRAN

Pourquoi vous devez consulter ce praticien

1 raison identifiée

Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche

Rhumatologue

RPPS 10000783976

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib 📇 Ajouter à mes contacts

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis

ACR open rheumatology · 2025

📚 5 citations🎯 RCR 2.28🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ObjectiveGlucagon‐like peptide 1 receptor agonists (GLP‐1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP‐1RAs have not been well studied in patients with rheumatoid arthritis (RA). We examined the effects of GLP‐1RAs on RA disease activity and cardiovascular risk profile in patients with RA and overweight or obesity.MethodsWe conducted a retrospective chart review study of patients with RA with a body mass index of ≥27 who were prescribed a GLP‐1RA (semaglutide or tirzepatide). Between 2018 and 2024, 173 patients with RA were identified in the treatment group (prescribed and took a GLP‐1RA), and 42 patients with RA were identified in the control group (prescribed but did not take GLP‐1RA). Patients were assessed at three‐month intervals for up to one year after prescription. Outcome measures included RA disease activity, cardiovascular risk markers, and patient‐reported outcomes. Changes in outcome measures within and between groups were assessed with linear mixed effect models, with adjustments for baseline characteristics that differed significantly between groups.ResultsGLP‐1RA–treated patients experienced significantly greater reductions in RA disease activity, pain, body weight, total cholesterol, and glycosylated hemoglobin than controls (P < 0.05). Within the treatment group, there were also significant reductions in erythrocyte sedimentation rate, C‐reactive protein values, low‐density lipoprotein cholesterol values, and triglyceride values (P < 0.05). Nearly one‐third of the treatment group discontinued the GLP‐1RA during the study period, with the most common adverse effect being gastrointestinal issues.ConclusionThis study suggests that the use of GLP‐1RAs can improve RA disease activity and cardiovascular risk profile. Although further research is needed, this novel finding has significant clinical implications because it suggests that anti‐obesity medications may improve both cardiovascular and RA outcomes.

A capsular polysaccharide from a healthy human microbiota member activates a Lag-3-NK cell axis to restrain colon cancer and augment immunotherapy

Cell reports · 2025

📚 4 citations🔓 Open Access

Prevalence and factors associated with metabolic syndrome and its components among overweight and obese reproductive-age women in Bac Giang, Vietnam

Scientific reports · 2025

📚 2 citations🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M VAN HUAN JOSEPH TRAN

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (26) — classées par pathologie

Transversal9

Revue générale5

Case report / série3

Épidémiologie & registres2

Essai clinique2

Pédiatrie2

Génétique1

Microbiote1

Pharmacovigilance1

Qualité de vie / PROMs1

Santé mentale / fatigue1

SAPL1

Partager cette fiche